Home / Company

Company

Invectys at the AACR meeting in Atlanta, March 2019

Invectys will be attending the AACR Annual Meeting 2019. The AACR (American Association for cancer Research) Annual Meeting program covers the latest discoveries…

Read more

4,3 Millions d’Euros de levés pour initier la Phase II

Après le succès de sa Phase I, Invectys lève 4.3 Millions d’Euros permettant la rentrée en Phase II de ses deux vaccins anticancéreux   Paris, le 12…

Read more

Invectys presents its INVAC-1 therapeutic vaccine Phase...

Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA Paris,…

Read more

Invectys at ASCO 2017 in Chicago : Clinical Oncology

Invectys attend ASCO 2017 meeting in Chicago  Invectys will be at the Annual Meeting is organized by American Society Of Clinical Oncology (ASCO). This meeting…

Read more

Mission and vision

Invectys focuses on the development of innovative anti-cancer therapeutic approaches in immunotherapy. It is backed by French and international private investors…

Read more

Invectys’ achievements

Main achievements Raised over 38 Millions € Moved 2 products into phase II clinical trials 15 patents filed Ongoing 2 phase II clinical trials in the USA and in…

Read more

About Invectys

Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. …

Read more

Scientific and Clinical Board

Invectys’ Scientific and Clinical Board is composed of globally recognized top specialists and key opinion leaders:   Professor Maurizio Zanetti University…

Read more